Biogen Inc. (ETR:IDP)
Germany · Delayed Price · Currency is EUR 109.15
-2.90 (-2.59%)
Jul 16, 2025, 5:35 PM CET
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
€1,194,232
Profits / Employee
€179,967
Market Cap
16.09B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Healthineers AG | 72,000 |
| Merck KGaA | 59,020 |
| Bayer Aktiengesellschaft | 91,864 |
| Fresenius SE & Co. KGaA | 176,486 |
| Fresenius Medical Care AG | 111,513 |
| Sartorius Aktiengesellschaft | 13,528 |
| Fielmann Group AG | 24,363 |
| Carl Zeiss Meditec AG | 5,730 |
Biogen News
- 16 days ago - Biogen starts phase 3 trial of felzartamab for kidney disease - Seeking Alpha
- 16 days ago - Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy - GlobeNewsWire
- 19 days ago - Biogen lauds benefits of higher dose Spinraza for spinal muscular atrophy - Seeking Alpha
- 19 days ago - New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA - GlobeNewsWire
- 20 days ago - Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma - Benzinga
- 21 days ago - Biogen’s salanersen shows promise in SMA, heads toward registrational trials - Seeking Alpha
- 21 days ago - Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results - Wallstreet:Online
- 21 days ago - Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? - Investor's Business Daily